Fast Answers
Navigating insurance and reimbursement questions can be like finding your way through a maze. Let us help you cut through the confusion, so you can focus on caring for your patients.
On this page:
Sandostatin® Therapy Support Hotline
For fast answers, call the Sandostatin® Therapy Support Hotline:
1-877-LAR-HELP
(1-877-527-4357)
Monday through Friday,
8 AM to 7 PM EST
The Hotline provides a broad range of coverage and reimbursement assistance to help you avoid billing problems, and resolve them if they occur. Depending on your needs, the Hotline staff can help with:
- Verifying insurance coverage
- Exploring alternative reimbursement options if coverage is denied
- Assisting with billing and collections of denied claims
- Expediting calls for medical information
Our pledge is to provide a comprehensive selection of professional services designed to make your experience with once-a-month Sandostatin® LAR Depot (octreotide acetate for injectable suspension) as easy for you as it is for your patients.
Reimbursement Q & A
Q: When can I call 1-877-LAR-HELP?
A: Monday through Friday, 8 AM to 7 PM EST
Q: What can I call 1-877-LAR-HELP for?
A: Any information you need on acquisition, reimbursement, coding, and drug administration. You can also call 1-877-LAR-HELP for any other reason. Though the Sandostatin® Patient Care Consultants may not have the answer, they should be able to lead you to your answer.
Q: Do private medical insurance plans and Medicare cover Sandostatin® LAR Depot (octreotide acetate for injectable suspension)?
A: Yes, most do. To find out for sure, call 1-877-LAR-HELP, or for further explanation click here.
Q: Do private medical insurance plans cover immediate release Sandostatin® (octreotide acetate) Injection?
A: Yes, most do. To find out for sure, call 1-877-LAR-HELP, or for further explanation click here.
Q: What can I do if my patients are not covered for immediate release Sandostatin® Injection?
A: Qualifying patients can be enrolled in the Sandostatin® Starter Program that provides qualifying patients with access to daily immediate release Sandostatin® Injection.
Q: What can I do if a claim is denied?
A: There are several things you can do. For starters, you can review the patient's EOB form and document the medical necessity for the patient. For more information, call 1-877-LAR-HELP.
Important Safety Information
Carcinoid Syndrome:
Sandostatin® LAR Depot (octreotide acetate for injectable suspension) is indicated for long-term treatment of the severe diarrhea and flushing episodes associated with metastatic carcinoid tumors and for the long-term treatment of the profuse watery diarrhea associated with VIP-secreting tumors in patients in whom initial treatment with immediate release Sandostatin® (octreotide acetate) Injection has been shown to be effective and tolerated.
Important Safety Information:
As with immediate release Sandostatin® Injection, the most frequently reported drug-related adverse events were biliary disorders (62%), gastrointestinal disorders (14% to 38%), and injection-site pain (20% to 50%). Hypoglycemia (4%), hyperglycemia (27%), sinus bradycardia (19%), conduction abnormalities (9%), and arrhythmias (3%) have been reported.
The controlled clinical trials that support the marketing clearance for Sandostatin® LAR Depot did not include determination of effect on tumor size or rate of growth. Sandostatin® LAR Depot is not indicated for tumor shrinkage.
Acromegaly
Sandostatin® LAR Depot (octreotide acetate for injectable suspension) is indicated for long-term maintenance therapy in acromegalic patients who have had an inadequate response to surgery and/or radiotherapy, or for whom surgery and/or radiotherapy is not an option. The goal of treatment in acromegaly is to reduce GH and IGF-1 levels to normal.
Important Safety Information:
As with immediate release Sandostatin® Injection, the most frequently reported drug-related adverse events were biliary disorders (52%), gastrointestinal disorders (7% to 36%), and injection-site pain (2% to 11%). Hypoglycemia (2%), hyperglycemia (15%), and hypothyroidism (2%) have been reported. While not measured in acromegalic patients receiving Sandostatin® LAR Depot, ECG changes have been reported in patients receiving immediate release Sandostatin® Injection; the degree to which these abnormalities are related to octreotide acetate is not clear, as many acromegalics have cardiovascular disease. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
